DEC TIMOTHY C 4

What Happened
Timothy C. Dec, Senior Vice President & Chief Financial Officer of Supernus Pharmaceuticals (SUPN), converted a tranche of performance-based equity into common stock on March 6, 2026. The filing shows four derivative conversion entries of 3,000 shares each (totaling 12,000 PSUs converted). To satisfy tax withholding, the company withheld 2,883 shares (1,433 and 1,450 shares) at $54.73 per share, producing cash value withheld of $78,428 and $79,359 (total ≈ $157,787). The exercise/conversion price for the PSUs is listed as $0.00 (no cash exercise price).

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (timely filing).
• Conversion: four derivative (M) entries of 3,000 shares each → 12,000 PSUs converted into common stock.
• Tax withholding (F): 1,433 shares withheld = $78,428; 1,450 shares withheld = $79,359; total withheld ≈ $157,787 at $54.73/share.
• Exercise/conversion price: $0.00 per share (PSU settlement, not a cash purchase).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — shares withheld to satisfy tax withholding for vested Performance Share Units; F2 — the PSUs were originally awarded Feb 22, 2024, with a portion vesting upon achievement of individual objectives set June 24, 2024.

Context
This was a vesting/settlement of Performance Share Units (PSUs), not an open-market buy or sale by the insider. The withholding of shares to cover taxes is a routine corporate practice (a net or “cashless” settlement of equity awards) and does not necessarily signal the insider’s market view. No 10b5-1 plan or gift is indicated in the excerpt.